Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$2.98 -3.18%

-$0.16 today

Market cap
$69.90M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.07M

Average 0.16M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$10.74M

FY 2025 · Annual

Investing Cash Flow

-$1.16M

FY 2025 · Annual

Financing Cash Flow

$20.39M

FY 2025 · Annual

+27.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.89M)(12.24M)(7.99M)(14.88M)(21.23M)
Depreciation & Amortization16.13K27.36K27.36K27.36K27.36K
Deferred Income Tax399.68K0000
Stock-Based Compensation233.22K207.35K872.25K2.66M4.29M
Change in Working Capital739.17K751.84K(4.64M)1.88M3.88M
Accounts Receivables00(7.5M)7.5M0
Inventory00000
Accounts Payables665.17K845.28K298.82K477.45K(527.01K)
Other Working Capital74K(93.45K)2.56M(6.1M)4.41M
Other Non-Cash Items(399.68K)4.02M543.19K25K2.29M
Operating Cash Flow(3.9M)(7.24M)(11.19M)(10.29M)(10.74M)
Capital Expenditures(136.8K)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(525K)(543.19K)(25K)0
Investing Cash Flow(136.8K)(525K)(543.19K)(25K)(1.16M)
Debt Repayment010.47M000
Common Stock Issued1.32K15838.34M14M20.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(341.9K)(1.11M)89.95K2.02M0
Financing Cash Flow(340.58K)9.36M38.43M16.03M20.39M
Effect of Forex Changes00000
Net Change in Cash(4.38M)1.59M26.69M5.71M8.48M
Free Cash Flow(4.04M)(7.24M)(11.19M)(10.29M)(10.74M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$21.2M
+ D&A$27.4K
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
+ Working Capital$3.9M
+ Other Non-Cash$2.3M
= Operating Cash Flow-$10.7M
- Capex$0
= Free Cash Flow-$10.7M

Analysis

FY2025 free cash flow is -$10.7M. FCF conversion is 50.6% of net income. Operating cash flow was -$10.7M, with capex of $0. The largest bridge item is Stock-Based Comp at $4.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportOct 14, 2026
8-KCurrent reportOct 5, 2026
8-KCurrent reportSep 15, 2026

Does COYA generate free cash flow?

Coya Therapeutics, Inc. (COYA) generated -$10.74M of free cash flow in fiscal 2025.

How much operating cash flow does COYA produce?

Operating cash flow was -$10.74M, before capital expenditures of $0.00.